RESUMEN
Discharge bundles, comprising evidence-based practices to be implemented prior to discharge, aim to optimise patient outcomes. They have been recommended to address high readmission rates in patients who have been hospitalised for an exacerbation of chronic obstructive pulmonary disease (COPD). Hospital readmission is associated with increased morbidity and healthcare resource utilisation, contributing substantially to the economic burden of COPD. Previous studies suggest that COPD discharge bundles may result in fewer hospital readmissions, lower risk of mortality and improvement of patient quality of life. However, evidence for their effectiveness is inconsistent, likely owing to variable content and implementation of these bundles. To ensure consistent provision of high-quality care for patients hospitalised with an exacerbation of COPD and reduce readmission rates following discharge, we propose a comprehensive discharge protocol, and provide evidence highlighting the importance of each element of the protocol. We then review care bundles used in COPD and other disease areas to understand how they affect patient outcomes, the barriers to implementing these bundles and what strategies have been used in other disease areas to overcome these barriers. We identified four evidence-based care bundle items for review prior to a patient's discharge from hospital, including (1) smoking cessation and assessment of environmental exposures, (2) treatment optimisation, (3) pulmonary rehabilitation, and (4) continuity of care. Resource constraints, lack of staff engagement and knowledge, and complexity of the COPD population were some of the key barriers inhibiting effective bundle implementation. These barriers can be addressed by applying learnings on successful bundle implementation from other disease areas, such as healthcare practitioner education and audit and feedback. By utilising the relevant implementation strategies, discharge bundles can be more (cost-)effectively delivered to improve patient outcomes, reduce readmission rates and ensure continuity of care for patients who have been discharged from hospital following a COPD exacerbation.
Asunto(s)
Alta del Paciente , Enfermedad Pulmonar Obstructiva Crónica , Humanos , Calidad de Vida , Readmisión del Paciente , Hospitales , Enfermedad Pulmonar Obstructiva Crónica/terapiaRESUMEN
BACKGROUND: Inhaled medications are central to treating asthma and chronic obstructive pulmonary disease (COPD), yet critical inhaler technique errors are made by up to 90% of patients. In the clinical research setting, recruitment of subjects with poor inhaler technique may give a false impression of both the benefits and the necessity of add-on treatments such as biologic therapies. OBJECTIVE: To assess the frequency with which inhaler technique is assessed and reliably optimized before and during patient enrollment into randomized controlled trials (RCTs) addressing the efficacy of topical therapy, and the escalation of therapy for asthma and COPD. METHODS: Systematic searches were conducted of PubMed and Embase for RCTs published in the past 10 years involving patients with a diagnosis of asthma or COPD undergoing escalation of baseline inhaled therapy (stepping up, changing, adding, switching, increasing, etc) or the introduction of biologic agents. RESULTS: Searches highlighted 1,014 studies, 118 of which were eligible after the removal of duplicates as well as screening and full text review. Of these, only 14 (11.9%) included accessible information in the methods section or referred to such information in online supplements or protocols concerning assessment of participants' inhaler technique. We therefore developed the proposed Best Practice Inhaler Technique Assessment and Reporting Checklist. CONCLUSIONS: Our study identifies a concerning lack of checking and correcting inhaler technique, or at least reporting that this was undertaken, before enrollment in asthma and COPD RCTs, which may affect the conclusions drawn. Mandating the use of a standardized checklist in RCT protocols and ensuring all published RCTs report checking and correcting inhaler technique before enrollment are important next steps.
Asunto(s)
Asma , Enfermedad Pulmonar Obstructiva Crónica , Administración por Inhalación , Asma/tratamiento farmacológico , Lista de Verificación , Humanos , Nebulizadores y Vaporizadores , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológicoRESUMEN
OBJECTIVE: To assess the incidence of hip fracture and all major osteoporotic fractures (MOF) in patients with chronic obstructive pulmonary disease (COPD) compared with non-COPD patients and to evaluate the use and performance of fracture risk prediction tools in patients with COPD. To assess the prevalence and incidence of osteoporosis. DESIGN: Population-based cohort study. SETTING: UK General Practice health records from The Health Improvement Network database. PARTICIPANTS: Patients with an incident COPD diagnosis from 2004 to 2015 and non-COPD patients matched by age, sex and general practice were studied. OUTCOMES: Incidence of fracture (hip alone and all MOF); accuracy of fracture risk prediction tools in COPD; and prevalence and incidence of coded osteoporosis. METHODS: Cox proportional hazards models were used to assess the incidence rates of osteoporosis, hip fracture and MOF (hip, proximal humerus, forearm and clinical vertebral fractures). The discriminatory accuracies (area under the receiver operating characteristic [ROC] curve) of fracture risk prediction tools (FRAX and QFracture) in COPD were assessed. RESULTS: Patients with COPD (n=80 874) were at an increased risk of fracture (both hip alone and all MOF) compared with non-COPD patients (n=308 999), but this was largely mediated through oral corticosteroid use, body mass index and smoking. Retrospectively calculated ROC values for MOF in COPD were as follows: FRAX: 71.4% (95% CI 70.6% to 72.2%), QFracture: 61.4% (95% CI 60.5% to 62.3%) and for hip fracture alone, both 76.1% (95% CI 74.9% to 77.2%). Prevalence of coded osteoporosis was greater for patients (5.7%) compared with non-COPD patients (3.9%), p<0.001. The incidence of osteoporosis was increased in patients with COPD (n=73 084) compared with non-COPD patients (n=264 544) (adjusted hazard ratio, 1.13, 95% CI 1.05 to 1.22). CONCLUSION: Patients with COPD are at an increased risk of fractures and osteoporosis. Despite this, there is no systematic assessment of fracture risk in clinical practice. Fracture risk tools identify those at high risk of fracture in patients with COPD.
Asunto(s)
Corticoesteroides/uso terapéutico , Fracturas Osteoporóticas/epidemiología , Fracturas Osteoporóticas/fisiopatología , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Corticoesteroides/efectos adversos , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fracturas Osteoporóticas/inducido químicamente , Modelos de Riesgos Proporcionales , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Curva ROC , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Reino Unido/epidemiologíaAsunto(s)
Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Corticoesteroides/administración & dosificación , Corticoesteroides/uso terapéutico , Agonistas Adrenérgicos beta/administración & dosificación , Agonistas Adrenérgicos beta/uso terapéutico , Quimioterapia Combinada , Humanos , Antagonistas Muscarínicos/administración & dosificación , Antagonistas Muscarínicos/uso terapéutico , Enfermedad Pulmonar Obstructiva Crónica/patología , Reino UnidoRESUMEN
This article considers the place of palliative and end of life care in the management of people with end-stage chronic obstructive pulmonary disease (COPD). This respiratory disease has considerable morbidity and mortality, which affect patients, their families and carers, and healthcare provision. Many nurses working with older people will encounter patients with advancing COPD which may be their main problem or part of multiple comorbidities. This article aims to help nurses recognise declining respiratory status and understand the challenges faced by this particular group of patients, their families and carers. It follows recommendations that end of life care should be considered and dealt with in this group of patients (Department of Health 2008, National Clinical Guideline Centre 2010). It explores palliation and end of life and then considers more practical applications to support nursing care at the end stage of the disease.
Asunto(s)
Cuidados Paliativos , Enfermedad Pulmonar Obstructiva Crónica/enfermería , Humanos , Enfermedad Pulmonar Obstructiva Crónica/mortalidad , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Cuidado TerminalRESUMEN
This is a timely book covering conditions other than cancer. intended for hospital nurses to enhance previous training and/ or experience, it does this through facts, questions, case studies and clinical alerts. it contains a useful list of acronyms, references and web links as well as a full-text personal digital assistant download. The discussion on withdrawing devices and interventions and a ventilator withdrawal algorithm are useful. Although written for the American market, there are many lessons for the UK.
RESUMEN
Anticholinergics have been used to treat obstructive respiratory disease for many years from historical preparations of the deadly nightshade genus, to the more recent developments ofipratropium, oxitropium, and tiotropium. The medical treatment of airways obstruction has focused on achieving maximal airway function through bronchodilators. Of the two main bronchodilators, beta2-agonists are often the first treatment choice although there is evidence of equivalence and some suggestions of the superiority of anticholinergics in chronic obstructive pulmonary disease (COPD). The following review looks at the background of anticholinergics, their pharmacological properties, and the evidence for use with suggestions for their place in the treatment of COPD.
Asunto(s)
Antagonistas Colinérgicos/uso terapéutico , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Antagonistas Colinérgicos/farmacocinética , Antagonistas Colinérgicos/farmacología , Tolerancia al Ejercicio , Humanos , Ipratropio/uso terapéutico , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Enfermedad Pulmonar Obstructiva Crónica/psicología , Calidad de Vida , Receptor Muscarínico M1/antagonistas & inhibidores , Receptor Muscarínico M2/antagonistas & inhibidores , Receptor Muscarínico M3/antagonistas & inhibidores , Derivados de Escopolamina/uso terapéutico , Bromuro de TiotropioRESUMEN
Over a year ago the National Institute for Clinical Excellence (NICE) commissioned national guidelines for managing chronic obstructive pulmonary disease (COPD) in both primary and secondary care. The resulting guidelines published earlier this year are the result of a systematic review of the evidence in the published literature and where this has not been available expert opinion has informed recommendations. The document makes over 200 recommendations for practice with seven key areas where it was felt that implementation of the recommendations would have the largest impact on the management of COPD. The result is a comprehensive document concentrating on the health aspects of COPD and the following article looks at the guidelines and concentrates on the seven priority areas.
Asunto(s)
Medicina Basada en la Evidencia , Guías de Práctica Clínica como Asunto , Enfermedad Pulmonar Obstructiva Crónica/diagnóstico , Enfermedad Pulmonar Obstructiva Crónica/terapia , Antiinflamatorios/uso terapéutico , Índice de Masa Corporal , Broncodilatadores/uso terapéutico , Volumen Espiratorio Forzado , Humanos , Desnutrición/diagnóstico , Desnutrición/etiología , Desnutrición/prevención & control , Estado Nutricional , Selección de Paciente , Enfermedad Pulmonar Obstructiva Crónica/complicaciones , Respiración Artificial , Índice de Severidad de la Enfermedad , Cese del Hábito de FumarRESUMEN
The marked female predominance in cases of idiopathic chronic cough and its association with mild chronic lymphocytic airway inflammation suggests an underlying autoimmune process. We set out to test the hypothesis that idiopathic chronic cough is associated with other organ-specific autoimmune diseases in a case control study. Twenty-two patients with idiopathic chronic cough and 65 community-matched controls for age and sex who responded to a self-administered questionnaire were asked about the presence of autoimmune disease, other medical problems and drug history. All subjects were invited to have a blood test for an autoimmune screen. Thirteen out of 22 (59%) patients with idiopathic chronic cough and eight out of 65 (12%) age- and sex-matched controls reported organ-specific autoimmune disease (odds ratio 8.8; 95% confidence interval 2.4-31.8, P<0.001). Organ-specific autoantibodies were present in a significantly higher proportion of cases than controls (40% vs. 13%; P = 0.047). These findings suggest a relationship between idiopathic chronic cough and organ-specific autoimmunity.
Asunto(s)
Enfermedades Autoinmunes/complicaciones , Tos/etiología , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Enfermedad Crónica , Femenino , Humanos , Masculino , Persona de Mediana Edad , Especificidad de ÓrganosRESUMEN
Chronic obstructive pulmonary disease carries a high morbidity and mortality and is one of the few chronic diseases where the number of people affected is rising, a trend that looks set to continue. Unfortunately patients often present at a late stage of the disease when therapeutic options are more limited and many patients are undertreated, overtreated or misdiagnosed. While patients present both in primary and secondary care it is primary care where the majority of patients are managed and where patients are likely to be seen at an earlier stage of the disease process when interventions are likely to be more effective. Therapeutic options for patients with COPD include pharmacological approaches and these should be prescribed on an individual basis and both subjective and objective criteria used in evaluating effectiveness.